ETNB vs. PRAX, OPK, ALXO, ZNTL, ARQT, SPRY, ABVX, OCUL, IMNM, and TYRA
Should you be buying 89bio stock or one of its competitors? The main competitors of 89bio include Praxis Precision Medicines (PRAX), OPKO Health (OPK), ALX Oncology (ALXO), Zentalis Pharmaceuticals (ZNTL), Arcutis Biotherapeutics (ARQT), ARS Pharmaceuticals (SPRY), ABIVAX Société Anonyme (ABVX), Ocular Therapeutix (OCUL), Immunome (IMNM), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical preparations" industry.
89bio (NASDAQ:ETNB) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation.
89bio has a net margin of 0.00% compared to Praxis Precision Medicines' net margin of -5,711.85%. 89bio's return on equity of -34.76% beat Praxis Precision Medicines' return on equity.
89bio received 73 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. However, 63.41% of users gave Praxis Precision Medicines an outperform vote while only 63.06% of users gave 89bio an outperform vote.
Praxis Precision Medicines has higher revenue and earnings than 89bio. 89bio is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.
67.8% of Praxis Precision Medicines shares are held by institutional investors. 2.8% of 89bio shares are held by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
89bio presently has a consensus target price of $28.14, suggesting a potential upside of 226.10%. Praxis Precision Medicines has a consensus target price of $105.80, suggesting a potential upside of 133.09%. Given 89bio's higher possible upside, equities analysts plainly believe 89bio is more favorable than Praxis Precision Medicines.
In the previous week, Praxis Precision Medicines had 13 more articles in the media than 89bio. MarketBeat recorded 32 mentions for Praxis Precision Medicines and 19 mentions for 89bio. Praxis Precision Medicines' average media sentiment score of 0.23 beat 89bio's score of -0.05 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.
89bio has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.87, meaning that its stock price is 187% more volatile than the S&P 500.
Summary
Praxis Precision Medicines beats 89bio on 9 of the 17 factors compared between the two stocks.
Get 89bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ETNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
